Efficacy observation of clinical medication guided by genetic testing of antipsychotic drugs in patients with schizophrenia
10.11886/scjsws20240226005
- VernacularTitle:基于抗精神病药物基因检测的住院精神分裂症患者临床用药的效果观察
- Author:
Haiyan WANG
1
;
Jianfeng CAO
1
;
Liping FU
1
;
Liangcheng XIANG
2
;
Tao TIAN
3
;
Jixiang WANG
1
;
Ming SHI
1
;
Xiaojun LI
1
;
Chunguang TANG
1
Author Information
1. Dazhou Minkang Hospital， Dazhou 635000， China
2. West China Second University Hospital， Sichuan University， Chengdu 610041， China
3. Ning'an Hospital of Ningxia Hui Autonomous Region， Yinchuan 750000， China
- Publication Type:Journal Article
- Keywords:
Drug genetic testing;
Schizophrenia;
Clinical efficacy;
Medication compliance;
Social function
- From:
Sichuan Mental Health
2024;37(5):420-426
- CountryChina
- Language:Chinese
-
Abstract:
BackgroundResults of genetic testing for antipsychotic drugs can guide the rational use of drugs in clinical practice and help improve the clinical symptoms of patients with schizophrenia. However， there is currently limited evidence in China regarding the impact of genetic testing results on medication adherence， social function and drug side effects of antipsychotic drug treatment. ObjectiveTo explore the improvement of clinical symptoms， medication adherence and social function in patients with schizophrenia under the guidance of antipsychotic drug gene testing results and examine the safety of drug treatment， so as to provide references for ifor precise treatment of schizophrenia patients. MethodsPatients with acute schizophrenia who received hospitalization at Dazhou Minkang Hospital from July 2019 to August 2021 as well as met the diagnostic criteria of the International Classification of Diseases， tenth edition （ICD-10） were selected as research subjects （n=144）. Based on random number table， subjects were divided into study group and control group， with 72 cases in each group. Control group received drug treatment based on the doctor's clinical experience， while study group received drug treatment based on the results of gene testing for antipsychotic drug. Both treatments lasted for 12 weeks. At baseline as well as 2， 4， 8 and 12 weeks after treatment， Positive and Negative Syndrome Scale （PANSS）， 8-item Morisky Medication Adherence Scale （MMAS-8）， Social Functional Rating Scale （SFRS） and Treatment Emergent Symptom Scale （TESS） were adopted for assessment. ResultTime effect and group effect of the reducing rate of PANSS， MMAS-8 and SFRS scores in the groups were statistically significant （Ftime=95.251， 6.650， 14.101， Fgroup=38.055， 58.175， 128.221， P<0.01）. The interaction effect of the reduction rates of MMAS-8 scores in two groups was statistically significant （Finteraction=5.837， P<0.01）. The group effect and interaction effect of the severity scores of drug side effects and patient pain scores in two groups were statistically significant （Fgroup=7.553， 81.533， Finteraction=8.693， 9.322， P<0.01）. ConclusionIn terms of improving clinical symptom relief， medication adherence， social function and drug side effects， medication for patients with schizophrenia guided by genetic testing of antipsychotic drugs may be more effective than that relying on medication based on clinical experience. ［Funded by 2019 Dazhou City Municipal Medical Research Project （number， 2019033）］
